Sinhal Ajay, Bennetts Jayme, Bhindi Ravinay, Cashman Kara, Deakin Anita, Gooley Robert, Heath Emma, Lorimer Michelle, Muller David, Ng Martin, Roberts-Thomson Ross, Walters Darren, Walton Antony, Whitbourn Robert, Wilson William, Yong Gerald, Camuglia Anthony
Department of Cardiology, Flinders Medical Centre, Flinders University, Adelaide, SA, Australia.
Department of Cardiothoracic Surgery, Victorian Heart Hospital, Monash University, Melbourne, Vic, Australia.
Heart Lung Circ. 2025 May;34(5):472-484. doi: 10.1016/j.hlc.2025.02.107. Epub 2025 Mar 18.
Transcatheter aortic valve implantation (TAVI) procedures performed in Australia are recorded in the national Australian Cardiac Outcomes Registry (ACOR) TAVI Registry. Characteristics of patients and operators are prospectively collected with reference to patient demographics, procedural factors as well as outcomes related to both efficacy and safety metrics.
Patient level data reported to the ACOR TAVI Registry from enrolled sites from registry inception up until 31 December 2021 were analysed. Key safety and efficacy metrics were identified and used to assess TAVI performance and outcomes in the Australian setting.
From 10 April 2018 to 31 December 2021, 9,881 consecutive patients underwent a TAVI procedure in Australia across 42 TAVI hospitals. The mean age of patients treated was 81.8 years (± standard deviation [SD] 7.1 years), 40.6% were female and the mean STS (Society for Thoracic Surgeons) score was 5.3% (±SD 4.4%). Overall, 0.3% of the cohort identified as Australian Aboriginal or Torres Strait Islander peoples. All-cause mortality at 30 days and 12 months was 1.37% and 5.57% respectively. The 30-day rates of stroke, major vascular complications and newly implanted permanent pacemaker were 2.19%, 1.23% and 10.68% respectively. There were 181 unique primary operators who performed TAVI during this time with an annualised median number of 19 procedures per operator per year (interquartile range [IQR] 42.5) and 63% of operators performed <30 cases per year.
TAVI is being performed in Australia with the encouraging outcomes described. These would appear to compare favourably with other international datasets.
在澳大利亚进行的经导管主动脉瓣植入术（TAVI）手术记录在澳大利亚国家心脏结局注册中心（ACOR）TAVI注册库中。患者和手术医生的特征通过前瞻性收集，涉及患者人口统计学、手术因素以及与疗效和安全性指标相关的结局。
分析了从注册库启动至2021年12月31日期间，参与注册的机构向ACOR TAVI注册库报告的患者层面数据。确定了关键的安全性和疗效指标，并用于评估澳大利亚环境下TAVI的手术表现和结局。
从2018年4月10日至2021年12月31日，澳大利亚42家TAVI医院的9881例连续患者接受了TAVI手术。接受治疗患者的平均年龄为81.8岁（±标准差[SD]7.1岁），40.6%为女性，平均胸外科医师协会（STS）评分为5.3%（±SD 4.4%）。总体而言，该队列中有0.3%的人被认定为澳大利亚原住民或托雷斯海峡岛民。30天和12个月时的全因死亡率分别为1.37%和5.57%。30天时的卒中、主要血管并发症和新植入永久性起搏器的发生率分别为2.19%、1.23%和10.68%。在此期间，有181名不同的主要手术医生进行了TAVI手术，每位手术医生每年的手术中位数为19例（四分位间距[IQR]42.5），63%的手术医生每年进行的病例数<30例。
澳大利亚正在开展TAVI手术，取得了令人鼓舞的结局。这些结局似乎优于其他国际数据集。
